Journal of Medicinal Chemistry · 2000 · 39 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsEnzyme InhibitionLead Compound DesignLigand BindingPeptidomimetic DesignPotency OptimizationStructure-activity Relationship AnalysisAmino AcidsCrystal Structure AnalysisDicarboxylic AcidsDirect Thrombin InhibitorsPeptidomimetic Library SynthesisProline-targeted InhibitorsStructure-based PeptidomimeticsThrombin Inhibition
With the aim to prepare nonpeptidic thrombin inhibitors, the amino acids of the thrombin-inhibiting tripeptide chain D-Phe-Pro-Arg were replaced with isosteres. Arg was replaced with the more rigid P1 truncated p-amidinobenzylamine (Pab), Pro with either cyclopentane-1, 2-dicarboxylic acid or cyclopentene-1,5-dicarboxylic acid, and D-Phe with a series of readily available lipophilic amines. One of the most potent compounds (25, pIC(50) = 6.01) in these series was cocrystallized with thrombin where the X-ray crystal structure provide insight to the structure-activity relationship (SAR).
23
Design principles for orally bioavailable drugs
Manuel A. Navia · Drug Discovery Today · 1996 · 205 citations
William Roush, Herbert R. Gillis, Albert I. Ko · Journal of the American Chemical Society · 1982 · 132 citations